Q4 FY2026 · ended Jun 30, 2026 · Revenue $16.11M, +6.4% YoY · Filed Sep 22, 2026
Aytu Biopharma, Inc. (AYTU) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q4 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $16.1 million and a net loss of $15,000. Free cash flow was $4.4 million. As of Jun 30, 2026 it held $26.3 million in cash and investments and $12.0 million in total debt.
Revenue
$16.11M
+6.4% vs year-ago quarter
Net income
$-15,000
+99.9% vs year-ago quarter
Operating cash flow
$4.41M
+57.2% vs year-ago quarter
Free cash flow
$4.39M
+205.1% vs prior quarter
EPS
$-0.53
-352.4% vs year-ago quarter
Dividend per share
None
Shares outstanding
10.87M
+9.6% vs year-ago quarter
Net cash
$14.28M
Q4 FY2026
Operating margin
-4.8%
Q4 FY2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AYTU (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Denver, CO
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1385818
- Former names
- AYTU BIOSCIENCE, INC (until Mar 22, 2021); Rosewind CORP (until Jun 8, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q4 FY2026 Jun 30, 2026 |
Q3 FY2026 Mar 31, 2026 |
Q2 FY2026 Dec 31, 2025 |
Q1 FY2026 Sep 30, 2025 |
Q4 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $16.1M | $12.4M | $15.2M | $13.9M | $15.1M |
| Operating income | -$777,000 | -$4.1M | -$2.0M | -$1.5M | -$7.6M |
| Net income | -$15,000 | -$5.6M | -$10.6M | $2.0M | -$19.8M |
| Diluted EPS | — | -$0.53 | -$1.05 | -$0.08 | — |
| Operating cash flow | $4.4M | -$4.2M | $3.7M | -$618,000 | $2.8M |
| Free cash flow | $4.4M | -$4.2M | $3.7M | -$618,000 | — |
| Total assets | $105.0M | $111.7M | $122.0M | $125.0M | $124.2M |
| Stockholders' equity | $35.3M | $35.1M | $14.2M | $23.2M | $19.0M |
| Cash and investments | $26.3M | $26.7M | $30.0M | $32.6M | $31.0M |
| Total debt | $12.0M | $12.5M | $13.0M | $13.5M | $13.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-K | Annual report | Sep 22, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Sep 22, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Agreement ended
|
Jun 25, 2026 | Jun 23, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | May 13, 2026 |
| 8-K |
Current report
Material agreement, Results of operations, Unregistered share sale, Change to shareholder rights
|
Apr 2, 2026 | Mar 31, 2026 |
All 907 Aytu Biopharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.